Roberts Wealth Advisors LLC Purchases Shares of 6,905 Gilead Sciences, Inc. (NASDAQ:GILD)

Roberts Wealth Advisors LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 6,905 shares of the biopharmaceutical company’s stock, valued at approximately $468,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Altfest L J & Co. Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at about $210,000. Federated Hermes Inc. increased its holdings in shares of Gilead Sciences by 4.9% in the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock worth $306,814,000 after purchasing an additional 175,925 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Gilead Sciences by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock worth $589,873,000 after purchasing an additional 87,482 shares during the last quarter. Wetzel Investment Advisors Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter worth about $74,000. Finally, Eagle Asset Management Inc. increased its holdings in shares of Gilead Sciences by 23.6% in the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock worth $25,724,000 after purchasing an additional 60,697 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Down 0.3 %

Shares of NASDAQ:GILD opened at $68.61 on Monday. The business has a 50 day simple moving average of $65.98 and a two-hundred day simple moving average of $72.51. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $87.86. The firm has a market capitalization of $85.48 billion, a PE ratio of 190.58, a price-to-earnings-growth ratio of 2.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same quarter in the previous year, the firm posted $1.37 earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. On average, equities analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.49%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Morgan Stanley reduced their target price on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 price target on shares of Gilead Sciences in a research report on Friday, June 14th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a research report on Wednesday, April 24th. Finally, Barclays dropped their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Twelve research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $83.47.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.